CN113891716A - 通过调节氨基酸水平治疗阿尔茨海默病的方法 - Google Patents
通过调节氨基酸水平治疗阿尔茨海默病的方法 Download PDFInfo
- Publication number
- CN113891716A CN113891716A CN202080036535.8A CN202080036535A CN113891716A CN 113891716 A CN113891716 A CN 113891716A CN 202080036535 A CN202080036535 A CN 202080036535A CN 113891716 A CN113891716 A CN 113891716A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- level
- phenylalanine
- mice
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01005—Tyrosine transaminase (2.6.1.5)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
提供用于调节氨基酸水平的试剂在制备用于在受试者中治疗阿尔茨海默病的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910720487.3A CN112336861A (zh) | 2019-08-06 | 2019-08-06 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
CN2019107204873 | 2019-08-06 | ||
PCT/CN2020/107238 WO2021023241A1 (zh) | 2019-08-06 | 2020-08-05 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113891716A true CN113891716A (zh) | 2022-01-04 |
Family
ID=74366465
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910720487.3A Pending CN112336861A (zh) | 2019-08-06 | 2019-08-06 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
CN202080036535.8A Pending CN113891716A (zh) | 2019-08-06 | 2020-08-05 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910720487.3A Pending CN112336861A (zh) | 2019-08-06 | 2019-08-06 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220280589A1 (zh) |
EP (1) | EP4011379A4 (zh) |
JP (1) | JP2022543014A (zh) |
KR (1) | KR20220044553A (zh) |
CN (2) | CN112336861A (zh) |
AU (1) | AU2020327259A1 (zh) |
BR (1) | BR112022001700A2 (zh) |
CA (1) | CA3148926A1 (zh) |
IL (1) | IL290195A (zh) |
MX (1) | MX2022001077A (zh) |
WO (1) | WO2021023241A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112336742A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途 |
CN115808492A (zh) * | 2021-09-14 | 2023-03-17 | 中国科学院深圳先进技术研究院 | 一种阿尔兹海默症生物标志物天冬酰胺及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408360A (zh) * | 2001-10-01 | 2003-04-09 | 青岛海洋大学 | 褐藻胶寡糖在抗衰老和抗痴呆中的应用 |
CN1562050A (zh) * | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
CN106344592A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用 |
CN108261425A (zh) * | 2017-12-31 | 2018-07-10 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种减轻阿尔茨海默病的功能性低聚糖组合物及其制备方法与应用 |
CN108283647A (zh) * | 2016-12-30 | 2018-07-17 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019074216A1 (ko) * | 2017-10-13 | 2019-04-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법 |
-
2019
- 2019-08-06 CN CN201910720487.3A patent/CN112336861A/zh active Pending
-
2020
- 2020-08-05 JP JP2022506311A patent/JP2022543014A/ja active Pending
- 2020-08-05 BR BR112022001700A patent/BR112022001700A2/pt unknown
- 2020-08-05 US US17/631,807 patent/US20220280589A1/en not_active Abandoned
- 2020-08-05 KR KR1020227007377A patent/KR20220044553A/ko not_active Application Discontinuation
- 2020-08-05 EP EP20850067.8A patent/EP4011379A4/en not_active Withdrawn
- 2020-08-05 CA CA3148926A patent/CA3148926A1/en active Pending
- 2020-08-05 CN CN202080036535.8A patent/CN113891716A/zh active Pending
- 2020-08-05 MX MX2022001077A patent/MX2022001077A/es unknown
- 2020-08-05 AU AU2020327259A patent/AU2020327259A1/en not_active Abandoned
- 2020-08-05 WO PCT/CN2020/107238 patent/WO2021023241A1/zh active Application Filing
-
2022
- 2022-01-27 IL IL290195A patent/IL290195A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408360A (zh) * | 2001-10-01 | 2003-04-09 | 青岛海洋大学 | 褐藻胶寡糖在抗衰老和抗痴呆中的应用 |
CN1562050A (zh) * | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
CN106344592A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用 |
CN108283647A (zh) * | 2016-12-30 | 2018-07-17 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物 |
CN108261425A (zh) * | 2017-12-31 | 2018-07-10 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种减轻阿尔茨海默病的功能性低聚糖组合物及其制备方法与应用 |
Non-Patent Citations (8)
Title |
---|
FRANCESCA PISTOLLATO, 等: "Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease", NUTRITION REVIEWS, vol. 74, no. 10, pages 624, XP055497740, DOI: 10.1093/nutrit/nuw023 * |
XINYI WANG, 等: "Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression", CELL RESEARCH, vol. 29, pages 787, XP036917064, DOI: 10.1038/s41422-019-0216-x * |
倪嘉缵;等: "阿尔茨海默病的防治策略研究进展", 深圳大学学报(理工版), vol. 30, no. 04, pages 331 - 348 * |
刘军莉;等: "肠道微生物群与阿尔茨海默病", 中国高原医学与生物学杂志, vol. 39, no. 03, pages 203 - 206 * |
刘秀勤, 等: "阿尔茨海默病患者尿液中17种游离氨基酸的分析", 卫生研究, vol. 41, no. 01, pages 113 * |
孔令娜, 等: "酸性寡糖对阿尔茨海默病模型小鼠脑内基因表达的影响", 药学学报, no. 12, pages 51 - 55 * |
张翠, 等: "基于UPLC-MS技术的阿尔茨海默病模型大鼠尿液代谢组学", 沈阳药科大学学报, vol. 35, no. 03, pages 3 - 4 * |
徐志强, 等: "阿尔茨海默病生物标志物及其检测技术研究概况", 中国老年学杂志, vol. 35, no. 21, pages 6317 - 6320 * |
Also Published As
Publication number | Publication date |
---|---|
CA3148926A1 (en) | 2021-02-11 |
AU2020327259A1 (en) | 2022-03-10 |
IL290195A (en) | 2022-03-01 |
WO2021023241A9 (zh) | 2021-11-04 |
KR20220044553A (ko) | 2022-04-08 |
EP4011379A1 (en) | 2022-06-15 |
BR112022001700A2 (pt) | 2022-03-22 |
US20220280589A1 (en) | 2022-09-08 |
MX2022001077A (es) | 2022-04-26 |
JP2022543014A (ja) | 2022-10-07 |
WO2021023241A1 (zh) | 2021-02-11 |
EP4011379A4 (en) | 2023-08-23 |
CN112336861A (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Olson et al. | The gut microbiota mediates the anti-seizure effects of the ketogenic diet | |
Wang et al. | Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression | |
US20220280578A1 (en) | Method for treating alzheimer's disease by regulating intestinal microorganisms | |
US20220280589A1 (en) | Method for treating alzheimer's disease by regulating amino acid level | |
US20220273598A1 (en) | Method for treating alzheimer's disease by inhibiting uptake of amino acids by t cells | |
US20220280541A1 (en) | Method for identifying carbohydrate drug-sensitive patient in patients having alzheimer's disease | |
Rejdak et al. | Decreased cerebrospinal fluid hypocretin‐1 (orexin A) in patients after repetitive generalized tonic–clonic seizures | |
RU2801150C1 (ru) | Способ лечения болезни альцгеймера посредством регуляции уровня аминокислот | |
RU2810079C2 (ru) | Способ лечения болезни альцгеймера посредством регуляции кишечных микроорганизмов | |
RU2791665C1 (ru) | Способ лечения болезни альцгеймера посредством ингибрования захвата аминокислот t-клетками | |
RU2806017C2 (ru) | Способ идентификации чувствительного к лекарственному средству на основе олигосахаридов маннуроновой кислоты пациента среди пациентов, имеющих болезнь альцгеймера | |
Chen et al. | Enhancing social behavior in an autism spectrum disorder mouse model: investigating the underlying mechanisms of Lactiplantibacillus plantarum intervention | |
Noble et al. | The gut microbiome regulates memory function | |
Bai et al. | frontiers ORIGINAL RESEARCH in Microbiology published: 02 November 2021 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060701 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |